Dr. Jolly is a co-founder of Tocagen, and previously co-founded Viagene, the world’s first gene therapy company. Dr. Jolly is an internationally recognized expert in the field of gene therapy and its industrial application. For most of the last twenty years he has been a senior biotechnology executive involved in translating gene-based products from research through clinical development at the following companies: Viagene, Inc., Chiron Corporation, Oxford BioMedica, Inc., and Advantagene, Inc., where he most recently served as President. These products included potential therapies for cancer, infectious diseases, and metabolic diseases. He has published over 100 scientific articles and is an inventor on over 45 issued patents. Highly respected as a pioneer in the clinical application and commercialization processes for gene therapy product candidates, Dr. Jolly has overseen numerous clinical trials and has extensive experience in moving new vector technologies through the regulatory processes required by federal agencies including the FDA, National Institutes of Health (NIH), and Recombinant DNA Advisory Committee (RAC). Before entering the biopharmaceutical industry, Dr. Jolly pursued his academic career in biophysics and molecular biology at the Weizmann Institute, Harvard Medical School, Scripps Clinic, the University of California, San Diego and The French National Institute for Health and Medical Research (INSERM) in Paris, France. He was born in the UK, received his education in Scotland, and holds a PhD in Biochemistry from the University of Glasgow. Dr. Jolly also currently serves on the Industrial Liaison and Translational Medicine Committees of the American Society of Gene and Cell Therapy (ASGCT).